US ophthalmic review最新文献

iDose TR Sustained-release Travoprost Implant for the Treatment of Glaucoma iDose TR缓释曲伏前列素植入物治疗青光眼

US ophthalmic review Pub Date : 2023-01-01 DOI: 10.17925/usor.2023.17.1.4

P. Ichhpujani, Sahil Thakur

引用次数: 1

New and Emerging Trabecular Meshwork Bypass Stents 新型和新兴小梁网旁路支架

US ophthalmic review Pub Date : 2023-01-01 DOI: 10.17925/usor.2023.17.1.10

W. Shalaby, M. Moster

引用次数: 0

Artificial Intelligence for the Diagnosis and Screening of Retinal Diseases 人工智能在视网膜疾病诊断和筛查中的应用

US ophthalmic review Pub Date : 2023-01-01 DOI: 10.17925/usor.2023.17.2.1

A. Arrigo, E. Aragona, F. Bandello

{"title":"Artificial Intelligence for the Diagnosis and Screening of Retinal Diseases","authors":"A. Arrigo, E. Aragona, F. Bandello","doi":"10.17925/usor.2023.17.2.1","DOIUrl":"https://doi.org/10.17925/usor.2023.17.2.1","url":null,"abstract":"Artificial intelligence (AI) is becoming established as a new method for analysing ophthalmological data, and unveiling new clinical and pathogenic insights into retinal diseases. AI-based algorithms are largely employed in the field of the most prevalent retinal diseases, including diabetic retinopathy, age-related macular degeneration and myopia. Several research groups are also testing AI in other retinal diseases, including inherited retinal dystrophies, retinopathy of prematurity, central serous chorioretinopathy and retinal vein occlusion. AI models are mainly used in screening of the fundus and structural optical coherence tomography images. However, more advanced methodologies are under investigation to extract clinically relevant information regarding the biomarkers of disease activity and outcome measures. AI is a powerful tool for increasing the amount of information obtained in clinical and research contexts. However, many issues still need addressing, including the resulting high demand for technology and resources, and the need for very large databases. Moreover, several ethical issues require debate, and specific rules are needed to govern the use of AI algorithms and check the quality of the analysed data. This article reviews the current use of AI in retinal diseases, unmet needs and future perspectives.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neurotrophic Keratitis: Exploring the Therapeutic Landscape 神经营养性角膜炎:探索治疗前景

US ophthalmic review Pub Date : 2023-01-01 DOI: 10.17925/usor.2023.17.1.36

Uma Balakrishnan, Samantha M Arsenault, Sumitra S. Khandelwal

引用次数: 0

Safety and Efficacy of Suprachorodial Injection of Triamcinolone Acetonide: Review of a Novel Treatment 脉络膜上注射曲安奈德的安全性和有效性:一种新型治疗方法的综述

US ophthalmic review Pub Date : 2023-01-01 DOI: 10.17925/usor.2023.17.1.25

Mohammad Jourieh

引用次数: 0

Submacular Choroidal Granuloma from Sarcoidosis: A Case Report 结节病所致黄斑下脉络膜肉芽肿1例

US ophthalmic review Pub Date : 2023-01-01 DOI: 10.17925/usor.2023.17.1.42

Jacob Duker, Priya Vakharia, J. Duker, L. Rifkin, C. Shah

{"title":"Submacular Choroidal Granuloma from Sarcoidosis: A Case Report","authors":"Jacob Duker, Priya Vakharia, J. Duker, L. Rifkin, C. Shah","doi":"10.17925/usor.2023.17.1.42","DOIUrl":"https://doi.org/10.17925/usor.2023.17.1.42","url":null,"abstract":"Introduction: This article reports two cases of submacular choroidal granuloma from sarcoidosis, highlighting the critical importance of timely diagnosis and treatment for both visual and systemic prognosis. Case studies: Case 1 is a 60-year-old man who presented with blurred vision from a submacular choroidal granuloma. Initially, the lesion responded to oral prednisone, however, there was progression once the prednisone was stopped. One year later, he developed complete heart block and was diagnosed with cardiac sarcoidosis. He underwent pacemaker implantation and has been maintained on mycophenolate. Case 2 is a 35-year-old man who presented with distortion from a submacular choroidal granuloma that similarly responded to oral prednisone but progressed after it was discontinued. He had a chest computerized tomography scan and a subsequent lymph node biopsy that confirmed the diagnosis of sarcoidosis. He has remained stable and healthy, with 20/20 vision on methotrexate. Conclusion: Submacular choroidal granuloma from sarcoidosis is a rare condition that can cause vision loss if not treated promptly. These lesions usually respond to local or systemic corticosteroids. Diagnosis of these lesions is critical not only for visual preservation but also to prevent systemic complications.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and Emerging Therapies for Leber Hereditary Optic Neuropathy Leber遗传性视神经病变的当前和新兴治疗方法

US ophthalmic review Pub Date : 2023-01-01 DOI: 10.17925/usor.2023.17.1.21

Pamela Davila-Siliezar, Noor Laylani, K. A. Douglas, D. Milea, Andrew G. Lee

{"title":"Current and Emerging Therapies for Leber Hereditary Optic Neuropathy","authors":"Pamela Davila-Siliezar, Noor Laylani, K. A. Douglas, D. Milea, Andrew G. Lee","doi":"10.17925/usor.2023.17.1.21","DOIUrl":"https://doi.org/10.17925/usor.2023.17.1.21","url":null,"abstract":"Leber hereditary optic neuropathy (LHON) is the most common primary mitochondrial DNA disorder, presenting typically as a sequential, painless, subacute, optic neuropathy in young males. Despite the very limited therapeutic options in LHON, recent developments involving novel pharmacological agents and emerging gene therapy interventions have shown promising results for improved visual outcomes. A synthetic analogue of coenzyme Q (idebenone) is the most common medical treatment in LHON. In a multicentre, double-blind randomized, placebo-controlled clinical trial (Rescue of Hereditary Optic Disease Outpatient Study [RHODOS]), a dose of 900 mg/day of idebenone for 24 weeks was found to be well tolerated and safe. In a follow-up study (RHODOS-OFU), the visual acuity of 70% of patients enrolled in RHODOS was reassessed 30 months after discontinuation of idebenone. Results from this study suggested that visual acuity continued to improve even after discontinuation of the drug. Gene therapy has recently emerged as a potential treatment for LHON. RESCUE and REVERSE were two phase III clinical trials of viral-mediated gene therapy using lenadogene nolparvovec intravitreal injections in patients with early-stage LHON. Results in these trials have shown long-term safety and bilateral visual acuity improvement after unilateral intravitreal injections at 96 weeks, and sustained visual improvement after 3 years of treatment. The most recent phase III clinical trial in LHON (REFLECT) has shown significant improvement of vision after bilateral intravitreal injections of lenadogene nolparvovec compared with unilateral injections. These promising results suggest that, in the near future, LHON might become the first mitochondrial disorder to benefit from gene therapy.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-dose Aflibercept with Increased Dosing Intervals as a New Standard of Care for DMO and nAMD 增加给药间隔的大剂量阿非利西普作为DMO和nAMD的新护理标准

US ophthalmic review Pub Date : 2023-01-01 DOI: 10.17925/usor.2023.17.1.8

S. Adrean

{"title":"High-dose Aflibercept with Increased Dosing Intervals as a New Standard of Care for DMO and nAMD","authors":"S. Adrean","doi":"10.17925/usor.2023.17.1.8","DOIUrl":"https://doi.org/10.17925/usor.2023.17.1.8","url":null,"abstract":"The introduction of vascular endothelial growth factor inhibitors has led to significant improvements for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO). Landmark trials – such as ANCHOR, MARINA and VIEW for nAMD and RIDE/RISE, VIVID and VISTA for DMO – showed positive results, including clinically meaningful gains in Early Treatment Diabetic Retinopathy Study letters, with anti-vascular endothelial growth factor agents now the standard of care for nAMD and DMO. More recent studies, including those investigating high-dose aflibercept in nAMD and DMO, have focused on durability of response by studying increased treatment intervals to reduce the treatment burden on patients and physicians alike. The PULSAR (nAMD) and PHOTON (DMO) trials included high-dose (8 mg) aflibercept at either 12-week or 16-week dosing intervals and showed non-inferior visual gains compared with the standard dose of 2 mg, with ≥83% of patients maintaining their extended dosing interval throughout the 48-week studies. This is certainly an exciting development, and it will be interesting to see how extended treatment durability will impact management paradigms for patients with nAMD and DMO.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The State of Preoperative Patient Education for Cataract Surgery 白内障手术术前患者教育现状

US ophthalmic review Pub Date : 2022-01-01 DOI: 10.17925/usor.2022.16.2.63

Brandon J. Baartman

引用次数: 0

Novel Molecule Lotilaner Could Potentially Offer Relief to Long-suffering Demodex Blepharitis Patients 新型分子洛替拉可能为长期遭受蠕形螨性眼睑炎的患者提供潜在的缓解

US ophthalmic review Pub Date : 2022-01-01 DOI: 10.17925/usor.2022.16.1.2

J. Meyer

引用次数: 0